<DOC>
	<DOCNO>NCT00882908</DOCNO>
	<brief_summary>The purpose study evaluate efficacy 4 different regimen TMC435 combination peginterferon alfa-2a ( PegIFNα-2a ) ribavirin ( RBV ) , define proportion patient sustain virologic response Week 72 ( patient undetectable plasma HCV RNA [ le 25 IU per mL undetectable ] end treatment Week 72 ) , compare control group receive PegIFN RBV combination TMC435-matched placebo .</brief_summary>
	<brief_title>A Study TMC435 Combination With Pegylated Interferon Alp\Fa-2a Ribavirin Patients Infected With Genotype 1 Hepatitis C Virus Who Never Received Treatment</brief_title>
	<detailed_description>This randomize ( study medication assign chance ) , 5-arm , double-blind ( neither investigator participant know treatment participant receives ) , placebo-controlled ( inactive substance compare study medication test whether study medication real effect clinical study ) study compare efficacy , tolerability safety different TMC435 regimen combine peginterferon alfa-2a ( PegIFNα-2a ) ribavirin ( RBV ) versus PegIFNα-2a plus RBV alone adult treatment-naive patient chronic genotype 1 HCV infection . The study mainly consist 3 phase : screening phase ( approximately 6 week ) , treatment phase ( 48 week ) , follow phase ( 48 week ) . In treatment phase , patient divide 5 different arm 1:1:1:1:1 randomize ratio . In treatment arm 1 2 , patient receive 12 week therapy TMC435 along PegIFNα 2a RBV follow treatment PegIFNα 2a , RBV , TMC435-matched placebo . In treatment arm 3 4 , patient receive 24 week therapy TMC435 , PegIFNα 2a , RBV . In treatment arm 5 ( control group ) , patient receive PegIFNα 2a RBV 48 week TMC435 match placebo first 24 week . Collection blood sample efficacy evaluation do schedule visit throughout study . Safety evaluation adverse event , clinical laboratory test , physical examination , vital sign electrocardiogram monitor throughout study . The total duration study approximately 72 week initiation treatment .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Simeprevir</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>Patients document chronic genotype1 hepatitis C infection plasma HCV RNA &gt; 100,000 IU/mL screen Patients treated HCV Patients childbearing potential partner childbearing potential agree use 2 effective method contraception Patients cirrhosis evidence hepatic decompensation Coinfection human immunodeficiency virus ( HIV ) Any contraindication Pegasys Copegus therapy History , current medical condition could impact safety patient study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Hepatitis C</keyword>
	<keyword>TMC435</keyword>
	<keyword>Peginterferon alpha-2a</keyword>
	<keyword>PegIFNalpha-2a</keyword>
	<keyword>RBV</keyword>
	<keyword>Ribavirin</keyword>
	<keyword>Placebo</keyword>
</DOC>